Descriptor English: | Neuroleptic Malignant Syndrome | ||||||
Descriptor Spanish: |
Síndrome Neuroléptico Maligno
| ||||||
Descriptor Portuguese: | Síndrome Maligna Neuroléptica | ||||||
Descriptor French: | Syndrome malin des neuroleptiques | ||||||
Entry term(s): |
NMS (Neuroleptic Malignant Syndrome) NMSs (Neuroleptic Malignant Syndrome) Neuroleptic Induced Neuroleptic Malignant Syndrome Neuroleptic Malignant Syndrome, Neuroleptic Induced Neuroleptic Malignant Syndromes Neuroleptic-Induced Neuroleptic Malignant Syndrome Neuroleptic-Malignant Syndrome, Neuroleptic Induced Syndrome, Neuroleptic Malignant Syndromes, Neuroleptic Malignant |
||||||
Tree number(s): |
C10.228.140.079.737 C10.720.737 C25.723.705.600 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D009459 | ||||||
Scope note: | A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) |
||||||
Annotation: | caused by tranquilizing agents so do not use /chem ind |
||||||
Allowable Qualifiers: |
BL blood CF cerebrospinal fluid CL classification CN congenital CO complications DG diagnostic imaging DH diet therapy DI diagnosis DT drug therapy EC economics EH ethnology EM embryology EN enzymology EP epidemiology ET etiology GE genetics HI history IM immunology ME metabolism MI microbiology MO mortality NU nursing PA pathology PC prevention & control PP physiopathology PS parasitology PX psychology RH rehabilitation RT radiotherapy SU surgery TH therapy UR urine VE veterinary VI virology |
||||||
Previous Indexing: |
Basal Ganglia Diseases (1979-1984) Fever (1966-1984) Malignant Hyperthermia (1973-1984) Muscle Rigidity (1972-1984) Tranquilizing Agents, Major (1975-1984) |
||||||
Public MeSH Note: | 1986; see BASAL GANGLIA DISEASES 1985 |
||||||
History Note: | 1986(1985) |
||||||
DeCS ID: | 9650 | ||||||
Unique ID: | D009459 | ||||||
NLM Classification: | WL 307 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1986/01/01 | ||||||
Date of Entry: | 1984/06/05 | ||||||
Revision Date: | 2010/06/25 |
|
Neuroleptic Malignant Syndrome
- Preferred
Neuroleptic-Induced Neuroleptic Malignant Syndrome
- Narrower
Concept UI |
M0014713 |
Scope note | A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) |
Preferred term | Neuroleptic Malignant Syndrome |
Entry term(s) |
NMS (Neuroleptic Malignant Syndrome) NMSs (Neuroleptic Malignant Syndrome) Neuroleptic Malignant Syndromes Syndrome, Neuroleptic Malignant Syndromes, Neuroleptic Malignant |
Concept UI |
M0332878 |
Preferred term | Neuroleptic-Induced Neuroleptic Malignant Syndrome |
Entry term(s) |
Neuroleptic Induced Neuroleptic Malignant Syndrome Neuroleptic Malignant Syndrome, Neuroleptic Induced Neuroleptic-Malignant Syndrome, Neuroleptic Induced |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey